Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Active:	No
Cancer Type:	Breast Cancer Cervical Cancer Esophogeal Cancer Head and Neck Cancer Hodgkin Lymphoma Lung Cancer Lymphoma Stomach/ Gastric Cancer	NCT ID:	NCT03674567
Trial Phases:	Phase I Phase II	Protocol IDs:	FLX475-02 (primary) NCI-2019-00102
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	RAPT Therapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03674567

Summary

This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and
cohort expansion study to determine the safety and preliminary anti-tumor activity of
FLX475 as monotherapy and in combination with pembrolizumab.

The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort
expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential
cohorts treated with successively higher doses of FLX475 as monotherapy or in combination
with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage
1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with
pembrolizumab.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.